Symphogen A/S
- Country
- 🇩🇰Denmark
- Ownership
- Subsidiary
- Established
- 2000-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.symphogen.com
Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies
- Conditions
- MET Gene AmplificationNSCLCMET Gene MutationNon Small Cell Lung CancerOncology
- Interventions
- Drug: Sym015
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2022-06-22
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 57
- Registration Number
- NCT02648724
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: Sym004Drug: FOLFIRI
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2019-03-26
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 10
- Registration Number
- NCT02568046
- Locations
- 🇺🇸
Sharp Memorial Hosptal, San Diego, California, United States
🇺🇸Georgetown University Medical Center, Washington, District of Columbia, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
Sym004 vs Standard of Care in Subjects With Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: Sym004 (9/6 mg/kg)Drug: Sym004 (12 mg/kg)Other: Best Supportive Care (BSC)Drug: Fluorouracil (5-FU)Drug: Capecitabine
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2019-04-16
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 254
- Registration Number
- NCT02083653
- Locations
- 🇺🇸
Mercy Research, Springfield, Missouri, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Hematology - Oncology Associates of Treasure Coast, Port Saint Lucie, Florida, United States
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy
- Conditions
- Carcinoma, Squamous Cell of Head and Neck
- Interventions
- Drug: Sym004
- First Posted Date
- 2011-08-16
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 26
- Registration Number
- NCT01417936
- Locations
- 🇫🇷
3303; Centre Alexis Vautrin; Département d'Oncologie Médicale, Nancy, Vandoeuvre Les Nancy, France
🇩🇪4901; Universitätsklinikum Essen, Essen, Germany
🇩🇪4904; Universitätsklinikum Freiburg, Freiburg, Germany
Sym004 in Patients With Advanced Solid Tumors
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: Sym004
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2018-10-15
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 111
- Registration Number
- NCT01117428
- Locations
- 🇪🇸
Servicio de Oncología Médica, Hospital Universitario Virgen del Rocío, Sevilla, Spain
🇧🇪UZ Antwerp, Oncologie, Edegem, Belgium
🇪🇸Hospital Clínico Universitario de Valencia, Valencia, Spain
Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)
- Conditions
- Immune Thrombocytopenic Purpura
- Interventions
- Drug: Sym001
- First Posted Date
- 2008-07-21
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Symphogen A/S
- Target Recruit Count
- 61
- Registration Number
- NCT00718692
- Locations
- 🇩🇪
Reseach Site 4908, Halle, Germany
🇮🇳Aysha Hospital Pvt. Ltd., 9109, Chennai, India
🇮🇳Apollo Hospital, 9104, Hyderabad, India